

TELEPHONE 285-0644

PETER J. IANNUZZI, M.D.
JOHN A. R. MARINO, M.D.
445 PORTAGE ROAD
NIAGARA FALLS, NEW YORK

*all
attended
same
knowledge*

January 24, 1969

Herbert L. Ley, Jr., M.D.
Commissioner of Food & Drugs
Dept. of Health, Education & Welfare
Washington, D. C. 20204

Dear Dr. Ley,

I have just received information regarding an FDA order to withdraw Mysteclin-F from the available market.

Because of the unusual number of patients with diabetes, debilitated patients and elderly women with a history of candidiasis, I have found Mysteclin-F a very efficacious antibiotic in the suppression of monilial overgrowth. I am sure that you can appreciate that the prevention of this organism is important; especially in view of many recent reports in medical literature regarding it as a cause of increased mortality and morbidity.

I still believe in the old adage, "an ounce of prevention is worth a pound of cure." I strongly feel that the removal of this drug from the available market would be a definite inconvenience and detriment to the practice of medicine, especially as pertaining to the above mentioned patients.

Yours very truly,

John A. R. Marino
John A.R. Marino, M.D. /